Organovo pioneered a novel approach, leveraging 3D bioprinting to create human-like tissues for advanced drug profiling and therapy development. Organovo’s breakthrough technology aims to transform drug discovery by focusing on human primary cell 3D models that closely mimic disease processes, significantly improving the chances of clinical efficacy.
